Children treated for soft tissue sarcomas at greater risk of second cancers

A new study has found that although children treated for soft tissue sarcomas are surviving longer than they did in the past, they have an increased risk for second cancers, especially when initial treatment combined radiation and chemotherapy. This is according to analysis of data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute.

In their report, Dr. Rochelle E. Curtis and associates at the National Cancer Institute in Bethesda, Maryland, say other studies have also suggested this increased risk but those studies have been small in size, so she and her team conducted a large study to follow 1499 children who survived at least 1 year after a soft tissue sarcoma diagnosis - either rhabdomyosarcoma, fibromatous neoplasms, and other specified soft tissue sarcomas - between 1973 and 2000. The rates of malignancy were then compared with those expected in the general population based on gender, race, age, and calendar year.

Twenty seven of the children developed 28 second primary cancers, compared with the expected 4.5 cases. The most common second malignancies included acute myeloid leukaemia, cutaneous melanoma, and cancers of the oral cavity, breast, bone, and soft tissue.

This means that the relative risk was higher during the first 5 years of follow-up, about 12 times higher than expected, but decreased to 5-fold thereafter.

Other factors associated with higher risk included treatment since 1985 rather than earlier, age less than 10 years versus older and combined radiotherapy and chemotherapy compared with surgery alone.

The researchers found that the risk associated with combined therapy was highest for patients with fibromatous neoplasms, for whom the rate of second cancers was increased more than 70 times.

Dr. Curtis's group concluded that ' further studies of childhood soft tissue sarcoma survivors are needed to evaluate the independent and combined effects of therapy and genetic susceptibility in the development of various types of second cancers'.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study highlights inequities in emergency care for unintentional ingestions in children